Leiomyosarcoma - Pipeline Insight, 2022

DelveInsight's , "Leiomyosarcoma - Pipeline Insight, 2022," report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Leiomyosarcoma Understanding

Leiomyosarcoma: Overview

Leiomyosarcoma is a malignant (cancerous) tumor that arises from smooth muscle Cells There are essentially two types of muscles in the body - voluntary and involuntary. Smooth muscles are involuntary muscles - the brain has no conscious control over them. Smooth muscles react involuntarily in response to various stimuli. For example, smooth muscle that lines the walls of the digestive tract causes wave-like contractions (peristalsis) that aid in the digestion and transport of food. Smooth muscles in the salivary glands cause the glands to squirt saliva into the mouth in response to taking a bite of food. Smooth muscle in the skin causes goose bumps to form in response to cold. The symptoms of a leiomyosarcoma vary depending upon the exact location, size, and spread of the tumor. A leiomyosarcoma, especially in the early stages, may not be associated with any obvious symptoms (asymptomatic). General symptoms associated with cancer may occur including fatigue, fever, weight loss, a general feeling of ill health (malaise), and nausea and vomiting.

"Leiomyosarcoma - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Leiomyosarcoma pipeline landscape is provided which includes the disease overview and Leiomyosarcoma treatment guidelines. The assessment part of the report embraces, in depth Leiomyosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leiomyosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Leiomyosarcoma.
• In the coming years, the Leiomyosarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Leiomyosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Leiomyosarcoma treatment market. Several potential therapies for Leiomyosarcoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Leiomyosarcoma market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Leiomyosarcoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Leiomyosarcoma Emerging Drugs Chapters

This segment of the Leiomyosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Leiomyosarcoma Emerging Drugs

• Unesbulin (PTC596): PTC Therapeutics

Unesbulin is an investigational oral tubulin binding agent that arrests tumor cells in G2/M phase, including cancer stem cells, through the action of inhibiting tubulin polymerization. Unesbulin was discovered through PTC's proprietary discovery platform. Currently, it is in Phase II/III stage of clinical trial evaluation to treat Leiomyosarcoma.

• TTI-621: Trillium Therapeutics

TTI-621 (SIRPa-IgG1 Fc) is a decoy receptor that blocks CD47 and delivers an activating signal to effector cells such as macrophages through its IgG1 Fc region. This activating signal, which increases the likelihood of monotherapy activity, together with a lack of unwanted binding to red blood cells, provides TTI-621 with the potential to be the best-in-class CD47 blocking agent. Currently, it is in Phase II stage of clinical trial evaluation to treat Leiomyosarcoma.

Further product details are provided in the report……..

Leiomyosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Leiomyosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Leiomyosarcoma

There are approx. 18+ key companies which are developing the therapies for Leiomyosarcoma. The companies which have their Leiomyosarcoma drug candidates in the most advanced stage, i.e. phase II/III include, PTC Therapeutics.

• Phases

DelveInsight's report covers around 18+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Leiomyosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Leiomyosarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Leiomyosarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leiomyosarcoma drugs.

Leiomyosarcoma Report Insights

• Leiomyosarcoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Leiomyosarcoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Leiomyosarcoma drugs?
• How many Leiomyosarcoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Leiomyosarcoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Leiomyosarcoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Leiomyosarcoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• PTC Therapeutics
• Trillium Therapeutics
• Philogen
• Jazz Pharmaceuticals
• Clovis Oncology
• Bristol-Myers Squibb
• Merck KGaA
• Novartis
• Viracta Therapeutics, Inc.
• OncoResponse, Inc.
• Incyte Corporation
• BioAtla, Inc.
• EMD Serono
• TRACON Pharmaceuticals
• APIM Therapeutics

Key Products

• Unesbulin (PTC596)
• TTI-621
• L19TNF
• Lurbinectedin
• Rucaparib
• Nivolumab
• Avelumab
• Pazopanib
• Eribulin
• Nanatinostat
• OR2805
• Itacitinib
• CAB-AXL-ADC
• M6620
• YH001
• ATX-101